Virtu Financial LLC Takes $423,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Virtu Financial LLC bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,695 shares of the company’s stock, valued at approximately $423,000.

Several other institutional investors have also recently added to or reduced their stakes in NBIX. Capital Investment Advisory Services LLC purchased a new stake in Neurocrine Biosciences in the second quarter worth $43,000. NEXT Financial Group Inc grew its holdings in shares of Neurocrine Biosciences by 89.8% in the second quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock worth $47,000 after purchasing an additional 265 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Neurocrine Biosciences by 70.5% in the second quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock worth $51,000 after purchasing an additional 246 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in Neurocrine Biosciences in the 3rd quarter worth about $67,000. Finally, Golden State Wealth Management LLC increased its stake in Neurocrine Biosciences by 100.0% in the 2nd quarter. Golden State Wealth Management LLC now owns 1,000 shares of the company’s stock worth $84,000 after buying an additional 500 shares during the period. Hedge funds and other institutional investors own 97.13% of the company’s stock.

Shares of NBIX stock opened at $117.64 on Wednesday. The stock’s 50-day moving average is $106.19 and its 200 day moving average is $93.81. Neurocrine Biosciences, Inc. has a 1-year low of $64.72 and a 1-year high of $118.42. The company has a debt-to-equity ratio of 0.83, a current ratio of 7.08 and a quick ratio of 6.99. The company has a market cap of $10.83 billion, a P/E ratio of 534.73, a PEG ratio of 5.90 and a beta of 1.24.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Monday, November 4th. The company reported $0.56 EPS for the quarter, missing the Zacks’ consensus estimate of $0.63 by ($0.07). The firm had revenue of $222.09 million during the quarter, compared to the consensus estimate of $211.31 million. Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The business’s revenue for the quarter was up 46.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.52 earnings per share. On average, analysts anticipate that Neurocrine Biosciences, Inc. will post 0.82 EPS for the current year.

In related news, insider Dimitri E. Grigoriadis sold 10,188 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $100.34, for a total transaction of $1,022,263.92. Following the completion of the sale, the insider now owns 118,596 shares of the company’s stock, valued at $11,899,922.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Malcolm Lloyd-Smith sold 9,956 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $90.85, for a total transaction of $904,502.60. The disclosure for this sale can be found here. Insiders sold a total of 46,131 shares of company stock worth $4,745,275 over the last 90 days. Company insiders own 4.30% of the company’s stock.

NBIX has been the subject of several research reports. ValuEngine cut shares of Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Royal Bank of Canada set a $118.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Friday, September 6th. TheStreet raised shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research note on Tuesday, November 19th. BidaskClub upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Finally, Piper Jaffray Companies increased their price objective on Neurocrine Biosciences from $111.00 to $116.00 in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $105.72.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: What is a short straddle?

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.